Bristol-Myers Squibb has signed an agreement to acquire Inhibitex, Inc. for approximately $2.5 billion in cash. Inhibitex is a clinical-stage biopharmaceutical company developing products that can treat or prevent serious infections, with the primary focus on nucleotide/nucleoside analogs for the treatment of hepatitis C virus (HCV). Its lead HCV asset is INX-189, an oral nucleotide polymerase (NS5B) inhibitor in Phase II development that has shown potent antiviral activity. “The acquisition of...